Regeneron Pharmaceuticals, Inc. (REGN)
$
605.39
+13.54 (2.24%)
Key metrics
Financial statements
Free cash flow per share
28.3046
Market cap
62.5 Billion
Price to sales ratio
4.4337
Debt to equity
0.0920
Current ratio
4.9267
Income quality
0.8786
Average inventory
3.1 Billion
ROE
0.1477
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Regeneron Pharmaceuticals, Inc. is engaged in the discovery, invention, development, manufacturing, and commercialization of medicines for a range of diseases globally. The operating income ratio is 0.28 indicating the company's operational profitability margin. Its diverse product range includes EYLEA, which is used to treat conditions such as wet age-related macular degeneration and diabetic macular edema, alongside treatments for myopic choroidal neovascularization and various forms of diabetic retinopathy. The company also develops and markets Dupixent for atopic dermatitis and asthma in both adults and children, Libtayo for specific cancers, and Praluent for managing familial hypercholesterolemia and cardiovascular disease. Moreover, REGEN-COV is available for treating COVID-19, while Kevzara addresses rheumatoid arthritis in adults. Regeneron has also made strides in treating Zaire ebolavirus infections through Inmazeb and offers ARCALYST for various periodic syndromes, including familial cold auto-inflammatory syndrome. Furthermore, ZALTRAP is indicated for metastatic colorectal cancer, as the company continually innovates therapies for eye, allergic, inflammatory, cardiovascular, metabolic, infectious, and rare diseases, as well as cancer, pain, and hematologic conditions. The net income ratio stands at 0.31 reflecting the company's profitability margin, while the reported income before tax is 4,779,900,000.00 showcasing its pre-tax profitability. Additionally, the earnings per share (EPS) is reported at $40.90 indicating the company's profitability on a per-share basis. The company earned an interest income of $711,400,000.00 showcasing its financial investments. With a large market capitalization of $64,260,937,720.00 Regeneron is a dominant player in the biopharmaceutical industry, contributing significantly to the overall market landscape. The stock is priced at $591.85 positioning it in the higher-end market, and it has an average trading volume of 1,150,490.00 indicating moderate liquidity. As a key player in the Biotechnology industry, Regeneron drives innovation and growth, establishing its presence in the Healthcare sector. The company's collaborative efforts through various agreements with notable partners and institutions further reinforce its strategic positioning and commitment to advancing healthcare solutions.
Is Regeneron Pharmaceuticals, Inc. (REGN) a good investment?
Investing in Regeneron Pharmaceuticals, Inc. (REGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bullish outlook. Always conduct your own research before investing.
What is Regeneron Pharmaceuticals, Inc. (REGN)'s stock forecast?
Analysts predict Regeneron Pharmaceuticals, Inc. stock to fluctuate between $520.50 (low) and $1,211.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Regeneron Pharmaceuticals, Inc.'s market capitalization?
As of 2025-05-29, Regeneron Pharmaceuticals, Inc.'s market cap is $64,260,937,720, based on 106,148,000 outstanding shares.
How does Regeneron Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Regeneron Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Regeneron Pharmaceuticals, Inc. pay dividends?
Regeneron Pharmaceuticals, Inc. pays dividends. The current dividend yield is 0.14%, with a payout of $0.88 per share.
How can I buy Regeneron Pharmaceuticals, Inc. (REGN) stock?
To buy Regeneron Pharmaceuticals, Inc. (REGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for REGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Regeneron Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Regeneron Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $14,202,000,000 | EPS: $40.90 | Growth: 10.39%.
Where can I find Regeneron Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.regeneron.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Regeneron Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Regeneron Pharmaceuticals, Inc. stock?
All-time high: $1,211.20 (2024-08-27) | All-time low: $441 (2021-03-04).
What are the key trends affecting Regeneron Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
Earlier this year, biotech company 23andMe filed for bankruptcy. The harsh reality was that its business, while enticing to people who wanted to learn about their backgrounds via DNA testing kits, wasn't sustainable and its losses were simply mounting.
businesswire.com
DALLAS--(BUSINESS WIRE)-- #MaryKay--Mary Kay Inc., a global advocate for furthering young women's education and encouraging youth to follow their STEM dreams, returned for a second year as a Special Awards Organization at the Regeneron International Science and Engineering Fair (Regeneron ISEF) in Columbus, Ohio. Ten grants totaling nearly $10,000 were awarded to standout high school-aged students excelling in innovative projects spanning topics from finding cures for cancers affecting women to sustainabl.
zacks.com
REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.
globenewswire.com
First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM).
seekingalpha.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET Company Participants Mark Hudson - Senior Director of Investor Relations George D. Yancopoulos - Board Co-Chair, President and Chief Scientific Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Our next featured company, Regeneron, has always been known for its R&D engine.
zacks.com
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
invezz.com
Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe for $256 million in cash. The transaction, which excludes 23andMe's telehealth unit, is pending approval from a bankruptcy court, with the deal expected to close in the third quarter of 2025.
investopedia.com
Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.
nypost.com
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.
youtube.com
Jim Camer breaks down why he's keeping an eye on shares of Regeneron.
See all news
